BetterScholar BetterScholar

T. Fontanges

Gastroenterology, Journal of Hepatology, Liver international, Pharmacotherapy, World Journal of Gastroenterology, Alimentary Pharmacology and Therapeutics, European Journal of Gastroenterology and Hepathology, Antiviral Therapy Show more
9
Role
Title
Level Year L/R
🐜 Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
40 auth. C. Hézode, H. Fontaine, C. Dorival, F. Zoulim, D. Larrey, V. Canva, V. de Lédinghen, T. Poynard, D. Samuel, M. Bourliere, L. Alric, J. Raabe, J. Zarski, P. Marcellin, G. Riachi, ... P. Bernard, V. Loustaud-Ratti, O. Chazouilleres, A. Abergel, D. Guyader, S. Metivier, A. Tran, V. Di Martino, X. Causse, T. Dao, D. Lucidarme, I. Portal, P. Cacoub, J. Gournay, V. Grando-Lemaire, P. Hillon, P. Attali, T. Fontanges, I. Rosa, V. Petrov-sanchez, Y. Barthe, J. Pawlotsky, S. Pol, F. Carrat, J. Bronowicki 		8 2014
8
🐜
🐜 Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.
11 auth. X. Causse, H. Godinot, M. Chevallier, P. Chossegros, F. Zoulim, D. Ouzan, ... J. Heyraud, T. Fontanges, J. Albrecht, C. Meschievitz, C. Trépo 		8 1991
8
🐜
🐜 Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypocholesterolemia.
27 auth. M. Di Filippo, P. Moulin, P. Roy, M. Samson-Bouma, S. Collardeau-Frachon, S. Chebel-Dumont, N. Peretti, J. Dumortier, F. Zoulim, T. Fontanges, R. Parini, M. Rigoldi, F. Furlan, G. Mancini, D. Bonnefont-Rousselot, ... E. Bruckert, J. Schmitz, J. Scoazec, S. Charrière, S. Villar-Fimbel, F. Gottrand, B. Dubern, D. Doummar, F. Joly, M. E. Liard-Meillon, A. Lachaux, A. Sassolas 		6 2014
6
🐜
🐜 Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real‐life, observational study
9 auth. P. Marcellin, M. Chousterman, T. Fontanges, D. Ouzan, M. Rotily, M. Varastet, ... J. Lang, P. Mélin, P. Cacoub 		6 2011
6
🐜
🐜 5‐Fluorouracil—Induced Tako‐Tsubo—Like Syndrome
7 auth. C. Basselin, T. Fontanges, J. Descotes, P. Chevalier, B. Bui-xuan, G. Feinard, ... Q. Timour 		5 2011
5
🐜
🐜 Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study.
9 auth. P. Cacoub, D. Ouzan, P. Mélin, J. Lang, M. Rotily, T. Fontanges, ... M. Varastet, M. Chousterman, P. Marcellin 		5 2008
5
🐜
🐜 Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis – results of a nationwide survey
24 auth. J. Cadranel, P. Lahmek, X. Causse, G. Bellaiche, L. Bettan, T. Fontanges, A. Medini, J. Henrion, M. Chousterman, B. Condat, ... P. Hervio, P. Périac, C. Eugène, H. Moindrot, D. Grasset, O. Nouel, C. Pilette, N. Szostak-Talbodec, J. Cayla, S. Si-Ahmed, P. Dumouchel, A. Pariente, B. Lesgourgues, J. Denis 		5 2007
5
🐜
🐜 Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study
8 auth. P. Mélin, M. Chousterman, T. Fontanges, D. Ouzan, M. Rotily, J. Lang, ... P. Marcellin, P. Cacoub 		5 2010
5
🐜
🐜 Pegylated Interferon-α2b plus Ribavirin Therapy in Patients with Hepatitis C and Psychiatric Disorders: Results of a Cohort Study
8 auth. J. Lang, P. Mélin, D. Ouzan, M. Rotily, T. Fontanges, P. Marcellin, ... M. Chousterman, P. Cacoub 		4 2010
4
🐜